About upadacitinib

AbbVie’s (ABBV) upadacitinib is a selective Janus kinase-1 inhibitor presently under investigation for the treatment of rheumatoid arthritis, ulcerative colitis, psoriatic arthritis, and Crohn’s disease.

Upadacitinib: Opportunity for AbbVie’s Long-Term Growth?


In July 2017, AbbVie presented the results of its phase 3 SELECT-NEXT clinical trial. AbbVie conducted the trial for the evaluation of the safety and efficacy of upadacitinib for the treatment of patients with moderate to severe rheumatoid arthritis who did not adequately respond to traditional synthetic DMARDs (disease modifying anti-rheumatic drugs).

At 12 weeks, 64.0% and 66.0% of the patients receiving upadacitinib 15 mg (milligrams) and upadacitinib 30 mg, respectively, achieved 20.0% improvement in the American College of Rheumatology Criteria (or ACR20) compared to 36.0% for patients under the placebo.

Among patients receiving upadacitinib 15 mg and upadacitinib 30 mg, 38.0% and 43.0% of patients, respectively, achieved ACR50 (50.0% improvement in the American College of Rheumatology criteria), while 21.0% and 27.0% of patients achieved ACR70 (70.0% improvement in the American College of Rheumatology criteria), respectively. Only 15.0% and 6.0% of the patients on a placebo achieved ACR50 and ACR70, respectively.

At week 12, 48.0% of the patients receiving either upadacitinib 15 mg or upadacitinib 30 mg achieved low disease activity (or LDA) compared to only 17.0% of the patients receiving a placebo. Further, 31.0% and 28.0% of the patients receiving upadacitinib 15 mg and upadacitinib 30 mg, respectively, achieved clinical remission compared to 10.0% of patients receiving a placebo. In the SELECT-NEXT study, both doses of upadacitinib met all primary and secondary clinical endpoints.

Ongoing trials with upadacitinib

AbbVie is conducting a phase 3 SELECT-MONOTHERAPY trial for the evaluation of upadacitinib as a monotherapy for the treatment of individuals with rheumatoid arthritis who did not have an adequate response to methotrexate.

AbbVie is also conducting another phase 3 SELECT-BEYOND trial to compare upadacitinib to a placebo in individuals with rheumatoid arthritis on a stable dose of standard synthetic DMARDs who did not adequately respond or were intolerant to biologic DMARDs.

ABBVie anticipates upadacitinib to be commercialized by 2019. If approved, upadacitinib will directly compete with Pfizer’s (PFE) Xeljanz. In the anti-rheumatoid arthritis drugs market, AbbVie’s upadacitinib could also face stiff competition from Johnson & Johnson’s (JNJ) Remicade, Pfizer’s Celebrex, Amgen’s (AMGN) Enbrel, Bristol-Myers Squibb’s Orencia, and others. The Vanguard Health Care ETF (VHT) invests ~3.13% of its total portfolio holdings in AbbVie.

Latest articles

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.

Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.

Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.

14 Jun

IEA Again Slashes Its Oil Demand Growth Estimate

WRITTEN BY Rabindra Samanta

As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.

Amazon is discontinuing its Amazon Restaurants service, which has been delivering food for restaurants in parts of the United States. Amazon Restaurants launched in the United States in 2015 and entered the British market the following year. However, it met strong opposition in the British market.